May 20, 2020 / 11:52 AM / 9 days ago

BRIEF-Myriad Receives FDA Approval Of BRACAnalysis CDx As A Companion Diagnostic For Lynparza In HRR-mutated Metastatic Castration-Resistant Prostate Cancer

May 20 (Reuters) - Myriad Genetics Inc:

* MYRIAD RECEIVES FDA APPROVAL OF BRACANALYSIS CDX® AS A COMPANION DIAGNOSTIC FOR LYNPARZA® IN HRR-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below